Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Status of the Claims
1. Claims 1-45 are the original claims filed 5/1/2024. In the Preliminary Amendment of 7/15/2024, claims 1-45 are canceled and new claims 46-61 are added.
Claims 46-61 are all the claims.
Priority
2. USAN 18/652,676 filed 05/01/2024, is a Divisional of 18/451,047, filed 08/16/2023, now U.S. Patent # 12312408, 18/451,047 is a Continuation of PCT/EP2022/054011, filed 02/17/2022, claims foreign priority to GB2111685.0, filed 08/14/2021, and claims foreign priority to GB 2102224.9, filed 02/17/2021.
Information Disclosure Statement
3. As of 9/23/2026, a total of two (2) IDS are filed: 7/15/2024; and 7/28/2026. The corresponding initialed and dated 1449 is considered and or record.
Objections
Specification
4. The disclosure is objected to because of the following informalities:
a) The use of the term ATCC, NCBI, BiTE, eFLUOR, CellTrace, Opera Phenix, CellCarrier, MACSquant, LIVE/DEAD, Celltrace, Vioblue, Tween, Langmuir, DELFIA, flowlogic, Expi293, UniProt, which is a trade name or a mark used in commerce, has been noted in this application. The term should be accompanied by the generic terminology; furthermore the term should be capitalized wherever it appears or, where appropriate, include a proper symbol indicating use in commerce such as ™, SM , or ® following the term.
Although the use of trade names and marks used in commerce (i.e., trademarks, service marks, certification marks, and collective marks) are permissible in patent applications, the proprietary nature of the marks should be respected and every effort made to prevent their use in any manner which might adversely affect their validity as commercial marks.
b) The figure legends for Figures 4A-4C, 22A-22D, 23-25 and 32B are objected to for failing to include the sequence identifiers for the amino acid sequences > 4 amino acids in length pursuant to 37 CFR 1.821-1.825.
c) Amend the specification to replace “^” with “-“.
d) Replace the term “eFLOUR” with “eFLUOR.”
e) Amend the specification to replace “oC” with “ºC”.
f) The specification is objected to for failing to include the sequence identifiers for the amino acid sequences > 4 amino acids in length pursuant to 37 CFR 1.821-1.825. See p. 158, lines 1-15.
g) The specification is objected to for skipping table numbering and labeling throughout. It is not obvious nor apparent why some tables are numbered/labeled, whilst others are not.
Appropriate correction is required.
Claim Objections
5. Claims 46-61 are objected to because of the following informalities:
a) Amend claims 46-61 to recite “or antibody fragment thereof”.
Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
6. Claims 46-61 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
a) Claims 46-61 are indefinite for reciting “SEQ ID NO:80” that is otherwise shown in the XML file of 5/1/2024 as a skipped sequence. The specification shows the sequence for SEQ ID NO: 80 in Table 23 as “DAS.” The phrase “SEQ ID NO:80” is required to be replaced with the actual sequence throughout the claim set. MPEP 2412.05(a).
b) Claim 61 is dependent on itself. The POSA cannot reasonably ascertain the intended subject matter for purposes of practicing the invention.
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Enablement
7. Claim 61 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.
Factors to be considered in determining whether undue experimentation is required, are summarized in In re Wands, 8 USPQ2d 1400 (Fed. Cir. 1988). They include the nature of the invention, the state of the prior art, the relative skill of those in the art, the amount of direction or guidance disclosed in the specification, the presence or absence of working examples, the predictability of the art, the breadth of the claims, the quantity of experimentation which would be required in order to practice the invention as claimed.
Claim interpretation
Claim 61 is dependent on itself. The POSA cannot reasonably ascertain the intended subject matter for purposes of practicing the invention.
“treatment”/ “treating”: the specification defines treating in a therapeutic sense or as a therapy and a subject in need thereof to which the antibody is administered to:
[0151] As used herein, “treating a disease or disorder” means reducing the frequency and/or severity of at least one sign or symptom of the disease or disorder experienced by a subject (compared to an earlier point in time, for example, prior to administration of any antibody).
[0042] In a further aspect of the invention there is provided a method of treating a disease or disorder in a subject, comprising administering to the subject a multispecific antibody of the invention, or a pharmaceutical composition of the invention. There is also provided a method of modulating an immune response in a subject, comprising administering to the subject a multispecific antibody of the invention, or a pharmaceutical composition of the invention. Administration of antibodies to a subject may be administration in a therapeutically effective amount.
[1470] According to a further aspect of the invention, there is provided method of treating a cancer in a subject in need thereof, comprising administering a therapeutically effective amount of the multispecific antibody as defined herein. Alternatively, a therapeutically effective amount of the pharmaceutical composition is administered.
Notably, claim 61 does not identify the entity that the administering step occurs within the method invention.
The claim scope for the disease much less the absence of a correlation between the ambiguous antibody being administered is infinite for all combinations.
The Patent Act requires that patent applicants describe the invention in explicit terms to enable any person skilled in the art to make and use the invention. 35 U.S.C. 112. Applicants method claim is infinite in scope for the disease and ambiguous for the intended antibody used in the method. The enablement requirement is a crucial aspect of the patent “bargain”: an inventor is granted limited protection from competition in exchange for publicly disclosing their new technology. See the decision in Morse, Incandescent Lamp, and Holland Furniture, establishing the requirement that if a patent claims an entire class or genus of processes, machines, or compositions of matter, the specification must enable a person skilled in the field to make and use the entire class. If a patent claims an entire class of processes, machines, manufactures, or compositions of matter, the patent’s specification must enable a person skilled in the art to make and use the entire class. In other words, the specification must enable the full scope of the invention as defined by its claims. The more one claims, the more one must enable. See §112(a); see also Continental Paper Bag Co. v. Eastern Paper Bag Co., 210 U. S. 405 (1908) (“[T]he claims measure the invention.”)
Examiner’s Comments
8. A non-statutory double patenting rejection was made against the instant application in USAN 17/674,120 (now US 12703746). The provisional rejection was withdrawn in the Office Action of 12/27/2024 for USAN 17/674,120 on the ground that “the copending claims do not currently recite the CDRs of the instant claims.”
9. Claims 51-55 comprising the VHCDR1-3, VLCDR1-3 and VH/VL domains for the anti-Vδ1 chain antibody clone, ADT1-4-2, are claimed in the multispecific antibody in copending Application No. 19/402,538 (reference application US 20260152558 A1) in claim 39(i). The distinction for the claims of ‘538 is for claim 39 (ii) drawn to a PD-L1 binding Fc region comprising a CH3 domain that comprises an AB structural loop comprising the amino acid sequence of SEQ ID NO: 565 or 569, and an EF structural loop comprising the amino acid sequence of SEQ ID NO: 567.
Conclusion
10. No claims are allowed.
11. Any inquiry concerning this communication or earlier communications from the examiner should be directed to LYNN A. BRISTOL whose telephone number is (571)272-6883. The examiner can normally be reached Mon-Fri 9 AM-5 PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu Julie can be reached at 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/LYNN A BRISTOL/Primary Examiner, Art Unit 1643